Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
Bianchini G, Pusztai L, Pienkowski T, Im YH, Bianchi GV, Tseng LM, Liu MC, Lluch A, Galeota E, Magazzù D, de la Haba-Rodríguez J, Oh DY, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Annals Of Oncology 2015, 26: 2429-2436. PMID: 26387142, DOI: 10.1093/annonc/mdv395.Peer-Reviewed Original ResearchContribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast cancers.
Bianchini G, Callari M, Iwamoto T, Riba M, Vigano' L, Locatelli A, Zambetti M, Karn T, Pusztai L, Gianni L. Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast cancers. Journal Of Clinical Oncology 2015, 33: 1081-1081. DOI: 10.1200/jco.2015.33.15_suppl.1081.Peer-Reviewed Original Research